Analyst Activity – Roth Capital Initiates Coverage On BioLineRx (NASDAQ:BLRX) With a Buy

Analyst Ratings For BioLineRx (NASDAQ:BLRX)

Story continues below

Today, Roth Capital initiated coverage on BioLineRx (NASDAQ:BLRX) with a Buy with a price target of $3.00.

There are 4 buy ratings on the stock.

The current consensus rating on BioLineRx (NASDAQ:BLRX) is Buy (Score: 3.00) with a consensus target price of $2.82 per share, a potential 168.57% upside.

Some recent analyst ratings include

  • 8/3/2017-Roth Capital initiated coverage with a Buy rating.
  • 2/13/2017-Rodman & Renshaw initiated coverage with a Buy rating.


    Recent Trading Activity for BioLineRx (NASDAQ:BLRX)
    Shares of BioLineRx closed the previous trading session at 1.05 down -0.02 -1.86% with 632,930 shares trading hands.

    An ad to help with our costs